Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing

Anticancer Research

Volumn 35, Issue 4, 2015, Pages 2029-2036

  Sykorova, Vlasta ^a   Dvorakova, Sarka ^a   Vcelak, Josef ^a   Vaclavikova, Eliska ^a   Halkova, Tereza ^a   Kodetova, Daniela ^b   Lastuvka, Petr ^b   Betka, Jan ^b   Vlcek, Petr ^b   Reboun, Martin ^c   Katra, Rami ^b   Bendlova, Bela ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c Charles University in Prague and General University Hospital in Prague   (Czech Republic)

Author keywords

Anaplastic thyroid carcinoma; Genetics; Next generation sequencing; Poorly differentiated thyroid carcinoma

Indexed keywords

ALCOHOL DEHYDROGENASE; ATM PROTEIN; B RAF KINASE; BIOLOGICAL MARKER; CADHERIN; CHECKPOINT KINASE 2; DNA GLYCOSYLASE MUTY; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYPICAN 3; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MSH2; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 1; SCATTER FACTOR RECEPTOR; TUBERIN; TUMOR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; ONCOGENE H RAS; POLYMERASE CHAIN REACTION; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; SOMATIC MUTATION; THYROID CARCINOMA; TUMOR GENE; VERY ELDERLY; CELL DIFFERENTIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MUTATION; PATHOLOGY; THYROID TUMOR;

CELL DIFFERENTIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84928397875     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Quiros RM, Ding HG, Gattuso P, Prinz RA and Xu X: Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103: 2261-2268, 2005.
2. Wang HM, Huang YW, Huang JS, Wang CH, Kok VC, Hung CM, Chen HM and Tzen CY: Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol 14: 3011-3018, 2007.
3. Sakamoto A, Kasai N and Sugano H: Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52: 1849-1855, 1983.
4. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G and Rosai J: Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31: 1256-1264, 2007.
5. Zivaljevic V, Tausanovic K, Paunovic I, Diklic A, Kalezic N, Zoric G, Sabljak V, Vekic B, Zivic R, Marinkovic J and Sipetic S: Age as a prognostic factor in anaplastic thyroid cancer. Int J Endocrinol 2014: 240513, 2014.
6. Smallridge RC, Marlow LA and Copland JA: Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16: 17-44, 2009.
7. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA and Nikiforov YE: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404, 2003.
8. Pita JM, Figueiredo IF, Moura MM, Leite V and Cavaco BM: Cell-cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J Clin Endocrinol Metab 99: E497-E507, 2014.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
10. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW and Sykorova V: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309: 1493-1501, 2013.
11. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH and Sýkorová V: Association between BRAF V600E mutation and recur rence of papillary thyroid cancer. J Clin Oncol 33: 42-50, 2015.
12. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK and Xing M: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/AKT and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93: 3106-3116, 2008.
13. Mochizuki K, Kondo T, Nakazawa T, Iwashina M, Kawasaki T, Nakamura N, Yamane T, Murata S, Ito K, Kameyama K, Kobayashi M and Katoh R: RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Histopathology 57: 444-450, 2010.
14. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML and Fusco A: RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4: 287-294, 1998.
15. Moura MM, Cavaco BM, Pinto AE and Leite V: High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96: E863-E868, 2011.
16. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20: 603-610, 2013.
17. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S and Bishop J: BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32: 2718-2726, 2014.
18. Salvatore G, Chiappetta G, Nikiforov YE, Decaussin-Petrucci M, Fusco A, Carney JA and Santoro M: Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-RAF and N-RAS point mutations. Eur J Cancer 41: 816-821, 2005.
19. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM and Maglott DR: ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42: D980-D985, 2014.
20. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249, 2010.
21. Kumar P, Henikoff S and Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073-1081, 2009.
22. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME and McVean GA: A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073, 2010.
23. Thorvaldsdóttir H, Robinson JT and Mesirov JP: Integrative Geno mics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14: 178-192, 2013.
24. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B: Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14: 719-729, 2007.
25. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ and Nikiforov YE: The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 99: E276-E285, 2014.
26. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G and Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753-1760, 1993.
27. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH and Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184, 1993.
28. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N and Akiyama M: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369-1371, 1992.
29. Wiseman SM, Masoudi H, Niblock P,Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D and Gilks B: Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 191: 581-587, 2006.
30. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC and Sobrinho-Simões M: E-Cadherin loss rather than betacatenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42: 580-587, 2003.
31. Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA and Lorch JH: Response and acquired resistance to evero limus in anaplastic thyroid cancer. N Engl J Med 371: 1426-1433, 2014.
32. Xu J, Filetti S and Hershman JM: Expression of hepatocyte nuclear factor-1alpha mRNA in human anaplastic thyroid cancer cell lines and tumors. Thyroid 1: 533-539, 2008.
33. Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle RM, Francis GL: Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol 53: 635-644, 2000.
34. Song CM, Kwon TK, Park BL, Ji YB and Tae K: Single nucleotide polymorphisms of ataxia telangiectasia mutated and the risk of papillary thyroid carcinoma. Environ Mol Mutagen doi: 10.1002/em.21898, 2014.
35. Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymańska A, Szymańska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA and Lubiński J: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75: 1131-1135, 2004.
36. Santos LS, Branco SC, Silva SN, Azevedo AP, Gil OM, Manita I, Ferreira TC, Limbert E, Rueff J and Gaspar JF: Polymorphisms in base excision repair genes and thyroid cancer risk. Oncol Rep 28: 1859-1868, 2012.
37. Karger S, Krause K, Engelhardt C, Weidinger C, Gimm O, Dralle H, Sheu-Grabellus SY, Kurt Werner S and Fuhrer D: Distinct pattern of oxidative DNA damage and DNA repair in follicular thyroid tumours. J Mol Endocrinol 48: 193-202, 2012.
38. Ruschenburg I, Vollheim B, Stachura J, Cordon-Cardo C and Korabiowska M: Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. Anticancer Res 26: 2107-2112, 2006.
39. Yamanaka K, Ito Y, Okuyama N, Noda K, Matsumoto H, Yoshida H, Miyauchi A, Capurro M, Filmus J and Miyoshi E: Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 73: 389-394, 2007.
40. Nikiforova MN, Wald AI, Roy S, Durso MB and Nikiforov YE: Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endo crinol Metab 98: E1852-E1860, 2013.